Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Xenon Pharmaceuticals Inc

XENE ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$62.35

▼ -2.93%

Market Cap $6.04B · Vol 235.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.04B

Mid Cap

Div Yield

N/A

EPS Growth

-6.88%

YoY

RSI (14)

39.29

Momentum

Beta

0.61

vs Market

52W High

$72.55

14.06% below

52W Low

$35.60

75.14% above

Volume

235.87K

Avg 352.97K

P/B

6.16

Price-to-book

ROE

-51.76%

Return on equity

Free Float

98.39%

Public shares

Shariah Compliance8 STANDARDS

✗ Xenon Pharmaceuticals Inc (XENE) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XENE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.59%

-7.36%

+11.34%

+50.31%

YTD

+39.11%

+64.25%

+66.89%

+237.94%

Financials & Valuation

TTM · Annual

Total Revenue	$7.50M
Net Income	$-345,910,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-4,974.27%
Net Profit Margin	-4,612.13%
ROE	-51.76%
ROA · ROIC	-48.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	473.62
P/B	6.16
P/FCF	N/A
EPS Growth	-6.88%
Outstanding Shares	96.84M

Technical Indicators

50-Day SMA	$61.16
200-Day SMA	$51.23
RSI (14)	39.29
Beta	0.61
52-Week High	$72.55
52-Week Low	$35.60

Volume Today	235.87K
Avg Daily Volume (30D)	352.97K
Relative Volume	0.67x
Volatility (10D)	30.71
Volatility (30D)	41.70
Free Float	98.39%

Analyst Consensus

BUY

Current Price $62.35

Mean Target $80.88

52W Low$35.60 52W High$72.55

Current

Target

$35.60 $72.55

Current Analyst target

+29.72% upside potential · 20 analysts

Identifiers

ExchangeNasdaq

FIGIBBG002VBMLS5

ISINCA98420N1050

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.